Thomas Morris

2.3k total citations
59 papers, 1.6k citations indexed

About

Thomas Morris is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Thomas Morris has authored 59 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Pulmonary and Respiratory Medicine, 19 papers in Oncology and 11 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Thomas Morris's work include Prostate Cancer Treatment and Research (35 papers), Prostate Cancer Diagnosis and Treatment (13 papers) and Radiopharmaceutical Chemistry and Applications (11 papers). Thomas Morris is often cited by papers focused on Prostate Cancer Treatment and Research (35 papers), Prostate Cancer Diagnosis and Treatment (13 papers) and Radiopharmaceutical Chemistry and Applications (11 papers). Thomas Morris collaborates with scholars based in United Kingdom, United States and Denmark. Thomas Morris's co-authors include Peter Iversen, J. Armstrong, Manfred P. Wirth, William A. See, David G. McLeod, Stuart McIntosh, Kristine Pemberton, Karim Fizazi, Celestia S. Higano and Judd W. Moul and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The Journal of Urology.

In The Last Decade

Thomas Morris

59 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas Morris United Kingdom	23	1.1k	338	295	235	234	59	1.6k
Sabine Brookman‐May Germany	19	1.1k 1.0×	327 1.0×	190 0.6×	361 1.5×	399 1.7×	125	1.7k
Anthony L. Patterson United States	23	1.2k 1.1×	213 0.6×	333 1.1×	200 0.9×	333 1.4×	44	1.6k
Lionel L. Bañez United States	26	1.4k 1.3×	525 1.6×	153 0.5×	477 2.0×	350 1.5×	75	2.1k
A. Akdaş Türkiye	19	1.8k 1.6×	507 1.5×	339 1.1×	281 1.2×	487 2.1×	102	2.7k
J.M. Wolff Germany	18	1.3k 1.1×	319 0.9×	123 0.4×	173 0.7×	576 2.5×	93	2.0k
Loı̈c Mourey France	16	882 0.8×	565 1.7×	101 0.3×	277 1.2×	271 1.2×	107	1.5k
Koji Mitsuzuka Japan	22	761 0.7×	215 0.6×	128 0.4×	214 0.9×	333 1.4×	117	1.5k
Larysa Rydzewska United Kingdom	16	1.0k 0.9×	317 0.9×	101 0.3×	181 0.8×	157 0.7×	33	1.5k
Peter Hammerer Germany	32	2.0k 1.8×	265 0.8×	285 1.0×	289 1.2×	460 2.0×	86	2.6k
Mindaugas Jievaltas Lithuania	14	1.0k 0.9×	217 0.6×	174 0.6×	304 1.3×	118 0.5×	65	1.3k

Countries citing papers authored by Thomas Morris

Since Specialization

Citations

This map shows the geographic impact of Thomas Morris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Morris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Morris more than expected).

Fields of papers citing papers by Thomas Morris

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Morris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Morris. The network helps show where Thomas Morris may publish in the future.

Co-authorship network of co-authors of Thomas Morris

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Morris. A scholar is included among the top collaborators of Thomas Morris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Morris. Thomas Morris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Miller, Claire, Roberto Sommavilla, Cindy L. O’Bryant, et al.. (2024). Pharmacokinetic study of capivasertib and the CYP3A4 substrate midazolam in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 94(2). 223–235. 1 indexed citations

Sommavilla, Roberto, et al.. (2023). The effect of food and acid‐reducing agents on the pharmacokinetic profile of capivasertib: Results from a randomized, crossover study. British Journal of Clinical Pharmacology. 89(11). 3330–3339. 9 indexed citations

Shore, Neal D., Begoña Mellado, Ralph J. Hauke, et al.. (2022). A Phase I Study of Capivasertib in Combination With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer. 21(2). 278–285. 15 indexed citations

Bakshi, Nasir, et al.. (2020). Spectrum of Myelodysplastic Syndrome in Patients Evaluated for Cytopenia(s). A Report from a Reference Centre in Saudi Arabia. Hematology/Oncology and Stem Cell Therapy. 15(2). 39–44. 5 indexed citations

Aujla, Hardeep, Tracy Kumar, Marcin Woźniak, et al.. (2018). Effect of sildenafil (Revatio) on postcardiac surgery acute kidney injury: a randomised, placebo-controlled clinical trial: the REVAKI-2 trial protocol. Open Heart. 5(2). e000838–e000838. 6 indexed citations

Rockwood, Neesha, Elsa Du Bruyn, Thomas Morris, & Robert J. Wilkinson. (2016). Assessment of treatment response in tuberculosis. Expert Review of Respiratory Medicine. 10(6). 643–654. 53 indexed citations

Moore, David, Clare Hodgson, Michael D. Brown, et al.. (2014). Quantification of skeletal metastases in castrate‐resistant prostate cancer predicts progression‐free and overall survival. British Journal of Urology. 114(6b). E70–E73. 22 indexed citations

Nelson, Joel B., Karim Fizazi, Kurt Miller, et al.. (2012). Phase 3, randomized, placebo‐controlled study of zibotentan (ZD4054) in patients with castration‐resistant prostate cancer metastatic to bone. Cancer. 118(22). 5709–5718. 91 indexed citations

Trump, Donald L., Heather Payne, Kurt Miller, et al.. (2011). Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration‐resistant prostate cancer. The Prostate. 71(12). 1264–1275. 16 indexed citations

10.

Tomkinson, Helen, et al.. (2010). An open-label, randomized, single-center, two-period, phase I, crossover study of the effect of zibotentan (ZD4054) on the pharmacokinetics of midazolam in healthy male volunteers. Clinical Therapeutics. 32(7). 1372–1386. 3 indexed citations

11.

Chouaïd, C., Faith E. Nathan, Kristine Pemberton, & Thomas Morris. (2010). A phase II, randomized, multicenter study to assess the efficacy, safety, and tolerability of zibotentan (ZD4054) in combination with pemetrexed in patients with advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology. 67(5). 1203–1208. 13 indexed citations

12.

Iversen, Peter, David G. McLeod, William A. See, et al.. (2010). Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow‐up of 9.7 years. British Journal of Urology. 105(8). 1074–1081. 78 indexed citations

13.

Morris, Thomas, et al.. (2009). Blister-like aneurysm of the anterior communicating artery. Journal of Clinical Neuroscience. 16(8). 1098–1100. 13 indexed citations

14.

James, Nicholas D., Armelle Caty, Michael Borre, et al.. (2008). Safety and Efficacy of the Specific Endothelin-A Receptor Antagonist ZD4054 in Patients with Hormone-Resistant Prostate Cancer and Bone Metastases Who Were Pain Free or Mildly Symptomatic: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 Trial. European Urology. 55(5). 1112–1123. 137 indexed citations

15.

Fleshner, Neil, et al.. (2007). Adjuvant androgen deprivation therapy augments cure and long-term cancer control in men with poor prognosis, nonmetastatic prostate cancer. Prostate Cancer and Prostatic Diseases. 11(1). 46–52. 10 indexed citations

16.

Hardy, Claire, et al.. (2007). Attitudes of prostate cancer patients towards the diagnosis and treatment of their disease: findings from a multinational survey. Current Medical Research and Opinion. 23(9). 2107–2116. 6 indexed citations

17.

Stranne, Johan, Jonas Hugosson, Peter Iversen, Thomas Morris, & Pär Lodding. (2005). Inguinal hernia in Stage M0 prostate cancer: A comparison of incidence in men treated with and without radical retropubic prostatectomy—an analysis of 1105 patients. Urology. 65(5). 847–851. 41 indexed citations

18.

McLeod, David G., Peter Iversen, William A. See, et al.. (2005). Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. British Journal of Urology. 97(2). 247–254. 196 indexed citations

19.

Iversen, Peter, et al.. (2003). Immediate Treatment with Bicalutamide 150mg as Adjuvant Therapy Significantly Reduces the Risk of PSA Progression in Early Prostate Cancer. European Urology. 44(5). 512–518. 24 indexed citations

20.

Iversen, Peter, et al.. (2001). Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer?. Prostate Cancer and Prostatic Diseases. 4(4). 196–203. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact